Feb 14 (Reuters) - The U.S. Food and Drug Administration (FDA) approved GSK's GSK.L combination vaccine to protect against meningococcal infection for use in individuals aged 10 through 25 years, the company said on Saturday.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.